Pacific Biosciences of California, Inc. (PACB) Return on equity 2016–2025
Pacific Biosciences of California, Inc. (PACB) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-10214.5%FY2025 · since FY2016: -87.8% → -10214.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -10214.5% | -10153.4 pp |
| FY2024 | -61.2% | -17.4 pp |
| FY2023 | -43.7% | +12.1 pp |
| FY2022 | -55.8% | -32.9 pp |
| FY2021 | -22.9% | -31.7 pp |
| FY2020 | 8.8% | +162.0 pp |
| FY2019 | -153.2% | -63.3 pp |
| FY2018 | -89.9% | +17.1 pp |
| FY2017 | -107.1% | -19.2 pp |
| FY2016 | -87.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More PACB financial trends
PACB RevenuePACB Net incomePACB Net marginPACB Gross profitPACB Gross marginPACB Operating incomePACB Operating marginPACB Operating cash flowPACB Free cash flowPACB Capital expendituresPACB Stock buybacksPACB Dividends paidPACB Total assetsPACB Total liabilitiesPACB Shareholders’ equityPACB overview →